Log in

NASDAQ:HARP - Harpoon Therapeutics Stock Price, Forecast & News

$11.45
-0.62 (-5.14 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$10.97
Now: $11.45
$12.14
50-Day Range
$10.74
MA: $14.11
$16.32
52-Week Range
$9.07
Now: $11.45
$21.47
Volume61,747 shs
Average Volume89,694 shs
Market Capitalization$285.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share

Profitability

Net Income$-55,570,000.00
Net Margins-962.70%

Miscellaneous

Employees45
Market Cap$285.56 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HARP shares have decreased by 12.4% and is now trading at $11.45. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Harpoon Therapeutics.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.05. The firm had revenue of $2.23 million for the quarter, compared to analysts' expectations of $3.53 million. Harpoon Therapeutics had a negative return on equity of 51.51% and a negative net margin of 962.70%. View Harpoon Therapeutics' earnings history.

What price target have analysts set for HARP?

6 equities research analysts have issued 1 year price targets for Harpoon Therapeutics' stock. Their forecasts range from $23.00 to $31.00. On average, they expect Harpoon Therapeutics' share price to reach $26.33 in the next twelve months. This suggests a possible upside of 130.0% from the stock's current price. View analysts' price targets for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News coverage about HARP stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a news impact score of -2.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutHarpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 289,000 shares, an increase of 12.8% from the February 27th total of 256,100 shares. Based on an average trading volume of 65,700 shares, the days-to-cover ratio is presently 4.4 days. Approximately 2.1% of the shares of the company are sold short. View Harpoon Therapeutics' Current Options Chain.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Precision BioSciences (DTIL), Intel (INTC), Kaleido Biosciences (KLDO) and Tcr2 Therapeutics (TCRR).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (3.69%), Fosun International Ltd (0.77%), State Street Corp (0.50%), Renaissance Technologies LLC (0.45%), Geode Capital Management LLC (0.35%) and CIBC World Markets Inc. (0.12%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View institutional ownership trends for Harpoon Therapeutics.

Which major investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Fosun International Ltd, and Goldman Sachs Group Inc.. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle. View insider buying and selling activity for Harpoon Therapeutics.

Which major investors are buying Harpoon Therapeutics stock?

HARP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, CIBC World Markets Inc., Russell Investments Group Ltd., Oxford Asset Management LLP, State Street Corp, UBS Group AG, and Barclays PLC. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin. View insider buying and selling activity for Harpoon Therapeutics.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $11.45.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $285.56 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe. View additional information about Harpoon Therapeutics.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]


MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel